Therapeutic Compositions

Abstract

The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.

1 . A product containing the compound of formula (I) below 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. 
     
     
         2 . A product according to  claim 1 , wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil. 
     
     
         3 . A product according to  claim 2 , wherein the compound having PDE5-inhibitory properties is tadalafil. 
     
     
         4 . A product according to  claim 2 , wherein the compound having PDE5-inhibitory properties is sildenafil. 
     
     
         5 . A product according to  claim 1 , wherein the disease wherein vasoconstriction is involved is selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction and angina pectoris. 
     
     
         6 . A pharmaceutical composition containing, as active principles, the compound of formula (I) as described in  claim 1 , or a pharmaceutically acceptable salt of said compound of formula (I), in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, as well as at least one excipient. 
     
     
         7 . A pharmaceutical composition according to  claim 6 , wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil. 
     
     
         8 . A pharmaceutical composition according to  claim 7 , wherein the compound having PDE5-inhibitory properties is tadalafil. 
     
     
         9 . A pharmaceutical composition according to  claim 7 , wherein the compound having PDE5-inhibitory properties is sildenafil. 
     
     
         10 . Use of the compound of formula (I) as described in  claim 1 , or a pharmaceutically acceptable salt of said compound of formula (I), in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament intended to treat a disease wherein vasoconstriction is involved. 
     
     
         11 . Use according to  claim 10 , wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil. 
     
     
         12 . Use according to  claim 10 , wherein the disease intended to be treated is selected from hypertension and pulmonary hypertension.